Stuart Naylor
Impact in
- Immunology top 5%
- Immunotherapy and Immune Responses
- Genetics top 5%
- Virus-based gene therapy research
Papers in
- Immunology 10
- Immunotherapy and Immune Responses 10
-
- Retinal Development and Disorders 6
- Wnt/β-catenin signaling in development and cancer 2
- Co-authors
- Richard Harrop (13 shared papers)Frances R. Balkwill (2 shared papers)William H. Shingler (9 shared papers)Trevor C. Dale (3 shared papers)Matthew John Smalley (3 shared papers)Frances Burke (1 shared paper)Helga Durbin (1 shared paper)Denis Talbot (1 shared paper)
- Journals
- Investigative Ophthalmology & Visual Science (4 papers)Clinical Cancer Research (4 papers)Human Gene Therapy (4 papers)Journal of Immunotherapy (4 papers)The Lancet (3 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Stuart Naylor
33 papers receiving 2.4k citations
Stuart Naylor's Hit Papers
Peers
Comparison fields: 5 of 64
- Immunology 369
- Genetics 290
- Molecular Biology 584
- Virology 43
- Neurology 114
Countries citing papers authored by Stuart Naylor
This map shows the geographic impact of Stuart Naylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Naylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Naylor more than expected).
Fields of papers citing papers by Stuart Naylor
This network shows the impact of papers produced by Stuart Naylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Naylor. The network helps show where Stuart Naylor may publish in the future.
Co-authors
The 25 scholars most cited alongside Stuart Naylor, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1987 | 376 | |
| 2 | Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial Hit paper breakdown → | 2014 | 376 |
| 3 | 1999 | 202 | |
| 4 | 2016 | 168 | |
| 5 | 2010 | 160 | |
| 6 | 2000 | 143 | |
| 7 | 2013 | 89 | |
| 8 | 2005 | 81 | |
| 9 | 2007 | 79 | |
| 10 | 2002 | 76 | |
| 11 | Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. | 2002 | 71 |
| 12 | 2007 | 71 | |
| 13 | 2009 | 68 | |
| 14 | 2009 | 65 | |
| 15 | 2012 | 54 | |
| 16 | 2008 | 51 | |
| 17 | 2008 | 50 | |
| 18 | 2008 | 45 | |
| 19 | 2001 | 42 | |
| 20 | 2009 | 41 |
About Stuart Naylor
Stuart Naylor is a scholar working on Immunology, Molecular Biology, Genetics, Ophthalmology and Cancer Research, having authored 36 papers that have together received 2.6k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (10 papers), Retinal Development and Disorders (6 papers), Virus-based gene therapy research (4 papers), Wnt/β-catenin signaling in development and cancer (2 papers), Erythropoietin and Anemia Treatment (1 paper), Cancer, Hypoxia, and Metabolism (1 paper), Writing and Handwriting Education (1 paper) and Nitric Oxide and Endothelin Effects (1 paper). The work is most often cited by research in Immunology (369 citations), Genetics (290 citations), Molecular Biology (584 citations), Virology (43 citations) and Neurology (114 citations). Stuart Naylor has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Richard Harrop, Frances R. Balkwill, William H. Shingler, Trevor C. Dale, Matthew John Smalley, Frances Burke, Helga Durbin, Denis Talbot, Jan H. Tavernier and Walter C. Fiers. Their work appears in journals such as Investigative Ophthalmology & Visual Science, Clinical Cancer Research, Human Gene Therapy, Journal of Immunotherapy and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.